

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 14863

STATEMENT BY EUGENE R. JOLLY, M.D., Ph.D.,
PRESIDENT
BIOMETRIC TESTING INC.,
661 PALISADE AVENUE/PO BOX 1388
ENGLEWOOD CLIFFS, NEW JERSEY 07632

BEFORE THE MONOPOLY SUBCOMMITTEE OF THE SENATE
SMALL BUSINESS COMMITTEE ON WEDNESDAY NOVEMBER 10,
1976 AT 10:00 A.M.

Senator Nelson, members of the subcommittee, it is a privilege to be here with you today to provide a summary of my findings resulting from clinical investigations of amphetamine and related drugs used as adjuncts in the treatment of obesity and my thoughts in regard to the applicability of these drugs in clinical medicine. It is a particular honor to discuss these matters with you, Senator Nelson, one of the truly distinguished citizens of my home state.

By way of introduction, Biometric Testing Inc. is an independent testing laboratory, engaged in clinical research performed for the food, drug, cosmetic and chemical industries on a contract basis. As a recognized clinical pharmacologist with over 20 years of experience in drug research and development, my technical function is to design appropriate studies on test products, closely monitor their progress, evaluate responses to the test products and provide a comprehensive interpretation of the data obtained. I should emphasize that I am a researcher and do not practice medicine.